Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Unknown 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Cancer Therapy-related Cardiovascular Toxicity 1

Interventions

Metformin 16Cyclophosphamide 15Drug Therapy 14Dexamethasone 14Cisplatin 14Cytarabine 11Gemcitabine 10Radiotherapy 9Carboplatin 9Vincristine 8Paclitaxel 8Oxaliplatin 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Unknown × tocilizumab × Clear all
NCT05855122 2023-06-02

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

The First Affiliated Hospital of Soochow University

Phase 4 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

NCT05730777 2023-02-16

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Peking University Third Hospital

Phase 4 Unknown
200 enrolled

Cancer Therapy-related Cardiovascular Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡